David Lebwohl
About
David Lebwohl is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, David Lebwohl has authored 31 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Lebwohl's work include Cancer Treatment and Pharmacology (12 papers), Angiogenesis and VEGF in Cancer (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). David Lebwohl is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Angiogenesis and VEGF in Cancer (5 papers) and Colorectal Cancer Treatments and Studies (4 papers). David Lebwohl collaborates with scholars based in United States, Germany and Switzerland. David Lebwohl's co-authors include Renzo Canetta, O M Rosen, Thomas J. Dull, A Ullrich, Chao‐Kai Chou, Roberto Gherzi, David Russell, Neal Rosen, Laura Sepp‐Lorenzino and Virginia M. Klimek and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
David Lebwohl
31 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| David Lebwohl United States | 18 | 1.8k | 1.1k | 562 | 390 | 360 | 31 | 3.2k | ||
| Ralf A. Hilger Germany | 27 | 1.3k 0.7× | 1.2k 1.1× | 410 0.7× | 618 1.6× | 374 1.0× | 83 | 3.2k | ||
| Herman Burger Netherlands | 28 | 1.2k 0.6× | 1.3k 1.1× | 526 0.9× | 330 0.8× | 246 0.7× | 45 | 2.6k | ||
| Sylvie M. Guichard United Kingdom | 33 | 2.3k 1.3× | 1.6k 1.4× | 202 0.4× | 319 0.8× | 445 1.2× | 96 | 4.0k | ||
| Steven D. Reich United States | 26 | 1.0k 0.6× | 787 0.7× | 261 0.5× | 532 1.4× | 353 1.0× | 73 | 2.3k | ||
| James J. Gibbons United States | 27 | 2.3k 1.3× | 706 0.6× | 361 0.6× | 509 1.3× | 337 0.9× | 77 | 3.8k | ||
| R. Osieka Germany | 28 | 1.1k 0.6× | 693 0.6× | 376 0.7× | 320 0.8× | 251 0.7× | 89 | 2.4k | ||
| William Westlin United States | 24 | 1.2k 0.7× | 545 0.5× | 218 0.4× | 211 0.5× | 555 1.5× | 65 | 3.0k | ||
| Rena G. Lapidus United States | 31 | 3.4k 1.9× | 1.6k 1.4× | 299 0.5× | 549 1.4× | 749 2.1× | 99 | 4.9k | ||
| Steven W. Elmore United States | 24 | 3.2k 1.8× | 1.2k 1.1× | 510 0.9× | 215 0.6× | 309 0.9× | 37 | 4.8k | ||
| Dona Alberti United States | 30 | 1.4k 0.8× | 1.0k 0.9× | 148 0.3× | 419 1.1× | 387 1.1× | 90 | 2.8k |
Countries citing papers authored by David Lebwohl
Since
Specialization
Citations
This map shows the geographic impact of David Lebwohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lebwohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lebwohl more than expected).
Fields of papers citing papers by David Lebwohl
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David Lebwohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lebwohl. The network helps show where David Lebwohl may publish in the future.
Co-authorship network of co-authors of David Lebwohl
This figure shows the co-authorship network connecting the top 25 collaborators of David Lebwohl. A scholar is included among the top collaborators of David Lebwohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lebwohl. David Lebwohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Cohn, Danny M., Padmalal Gurugama, Markus Magerl, et al.. (2024). CRISPR-Based Therapy for Hereditary Angioedema. New England Journal of Medicine. 392(5). 458–467.
2.
Fontana, Marianna, Scott D. Solomon, Liron Walsh, et al.. (2024). CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. New England Journal of Medicine. 391(23). 2231–2241.
3.
Ericson, Solveig G., Lamis Eldjerou, Eric Bleickardt, et al.. (2019). Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy. Current Hematologic Malignancy Reports. 14(1). 47–55.
4.
Gnant, Michael, José Baselga, Hope S. Rugo, et al.. (2013). Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. JNCI Journal of the National Cancer Institute. 105(9). 654–663.
5.
Drevs, Joachim, Michael Medinger, K. Mross, et al.. (2010). A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.. PubMed. 30(6). 2335–9.
6.
Tabernero, Josep, Federico Rojo, Emiliano Calvo, et al.. (2008). Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 26(10). 1603–1610.
7.
Sharma, Sunil, Bruno Morgan, Peter R. Allegrini, et al.. (2005). Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemotherapy and Pharmacology. 57(6). 761–771.
8.
Mross, K., Joachim Drevs, Michael Medinger, et al.. (2005). Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. European Journal of Cancer. 41(9). 1291–1299.
9.
Abraham, Jame, Manish Agrawal, Susan Bakke, et al.. (2003). Phase I Trial and Pharmacokinetic Study of BMS-247550, an Epothilone B Analog, Administered Intravenously on a Daily Schedule for Five Days. Journal of Clinical Oncology. 21(9). 1866–1873.
10.
DeMario, Mark, Mark J. Ratain, Nicholas J. Vogelzang, et al.. (1999). A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. Cancer Chemotherapy and Pharmacology. 43(5). 385–388.
11.
Hudis, Clifford A., Andrew D. Seidman, José Baselga, et al.. (1998). Lack of Increased Cardiac Toxicity with Sequential Doxorubicin and Paclitaxel. Cancer Investigation. 16(2). 67–71.
12.
Lebwohl, David & Renzo Canetta. (1998). Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. European Journal of Cancer. 34(10). 1522–1534.
13.
Bentel, Jacqueline M., David Lebwohl, Kevin J. Cullen, et al.. (1995). Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells. Journal of Cellular Physiology. 165(1). 212–221.
14.
Sepp‐Lorenzino, Laura, Zhengping Ma, David Lebwohl, Alexander Vinitsky, & Neal Rosen. (1995). Herbimycin A Induces the 20 S Proteasome- and Ubiquitin-dependent Degradation of Receptor Tyrosine Kinases. Journal of Biological Chemistry. 270(28). 16580–16587.
15.
Seidman, Andrew D., Larry Norton, Bonnie Reichman, et al.. (1994). Taxol (Paclitaxel) plus Recombinant Human Granulocyte Colony-Stimulating Factor in the Treatment of Metastatic Breast Cancer. Oncology. 51(1). 33–39.
16.
Sepp‐Lorenzino, Laura, Neal Rosen, & David Lebwohl. (1994). Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.. PubMed. 5(10). 1077–83.
17.
Reichman, Bonnie, Andrew D. Seidman, John Crown, et al.. (1993). Taxol and Recombinant Human Granulocyte Colony‐Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer. Annals of the New York Academy of Sciences. 698(1). 398–402.
18.
Hakes, Thomas, Bonnie Reichman, David Lebwohl, et al.. (1993). Phase II trial of carboplatin and etoposide in metastatic breast cancer. Cancer. 71(4). 1254–1257.
19.
Seidman, Andrew D., Larry Norton, Bonnie Reichman, et al.. (1993). Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.. PubMed. 20(4 Suppl 3). 40–5.
20.
Chou, Chao‐Kai, Thomas J. Dull, David Russell, et al.. (1987). Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin.. Journal of Biological Chemistry. 262(4). 1842–1847.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ralf A. Hilger Breakdown of academic impact, for papers by Herman Burger Breakdown of academic impact, for papers by Sylvie M. Guichard Breakdown of academic impact, for papers by Steven D. Reich Breakdown of academic impact, for papers by James J. Gibbons Breakdown of academic impact, for papers by R. Osieka Breakdown of academic impact, for papers by William Westlin Breakdown of academic impact, for papers by Rena G. Lapidus Breakdown of academic impact, for papers by Steven W. Elmore Breakdown of academic impact, for papers by Dona Alberti